Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. More about the company

$19.08
+0.42% today
$917M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

Steady

Edge

—

Is ODTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2026-05-08 → 2026-10-22
S? 24w
2026-05-082026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 24w current
Total tracked: 24 weeks across 1 stage run.

ODTX among Biotechnology570th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…570ODTX——−8.1%
vs 52W High
—
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 24
1w13w26w
Week 24, proven structure
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
—
—
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
0.49x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-8.1%
3M
+2.3%
6M
—
YTD
—
1Y
—
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-10-22S—
Wk 24 · Vol 0.49x
2026-10-21S—
Wk 23 · Vol 0.78x
2026-10-20S—
Wk 23 · Vol 1.11x
2026-10-19S—
Wk 23 · Vol 1.07x
2026-10-16S—
Wk 23 · Vol 0.79x
2026-10-15S—
Wk 23 · Vol 0.57x
2026-10-14S—
Wk 22 · Vol 0.89x
2026-10-13S—
Wk 22 · Vol 0.95x
2026-10-12S—
Wk 22 · Vol 1.04x
2026-10-09S—
Wk 22 · Vol 1.22x
2026-10-08S—
Wk 22 · Vol 1.57x
2026-10-07S—
Wk 21 · Vol 1.01x
Moving averages & range
50 DMA
$22.11
200 DMA
—
52W High
—
52W Low
—
5D Low
$17.17
Resistance levels (recent highs)
20d High
$22.44
60d High
$28.76
120d High
—
250d High
—
Next resistance
+17.6%
to 20d High
Dividend Yield
0.00%
P/B 2.2

Odyssey Therapeutics: quick answers

Which sector and industry is Odyssey Therapeutics in?

Odyssey Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.